Skip to main content
. 2020 Jul 16;6(1):e12050. doi: 10.1002/trc2.12050

FIGURE 7.

FIGURE 7

Percent of Phase 2 and 3 disease‐modifying therapy trials requiring amyloid evidence (positron emission tomography, cerebrospinal fluid or either) at entry: 2016–2020 (ClinicalTrials.gov accessed February 27, 2020) (Figure by Mike de la Flor)